Anavex Life Sciences Corp. (FRA:12X1)

Germany flag Germany · Delayed Price · Currency is EUR
4.091
-0.012 (-0.29%)
Last updated: Jan 28, 2026, 8:12 AM CET
-56.36%
Market Cap353.46M -62.2%
Revenue (ttm)n/a
Net Income-39.53M
EPS-0.46
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume505
Open4.091
Previous Close4.103
Day's Range4.091 - 4.091
52-Week Range2.261 - 11.505
Betan/a
RSI52.60
Earnings DateFeb 13, 2026

About Anavex Life Sciences

Anavex Life Sciences Corp. operates as a biopharmaceutical company. It engages in developing innovative treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, pain, and various types of cancer . Its lead drug candidate, ANAVEX 2-73 (blarcamesine), has completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease; a Phase 2 proof-of-concept study in Parkinson's disease dementia; and ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2004
Employees 34
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 12X1
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements